Harbin Pharmaceutical Group CoSHSE:600664 +0.96%78 EBITDA Margin % is 5.14% as of Mar. 2026, which is 35% below its 10-year median of 7.96. GuruFocus rates SHSE:600664 with a GF Score™ of 78/100 and a GF Value™ of ¥3.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 954 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks worse than 70.55% on this metric.
Harbin Pharmaceutical Group Co (SHSE:600664) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Harbin Pharmaceutical Group Co EBITDA Margin % Related Terms
Harbin Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co EBITDA Margin % Chart
SHSE:600664 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co (SHSE:600664) has a EBITDA Margin % of 5.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Harbin Pharmaceutical Group Co and its competitors. This is 35% below median its historical median of 7.96. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #673 out of 954 companies in the Drug Manufacturers industry, placing it in the top 70.5%.
Is Harbin Pharmaceutical Group Co's EBITDA Margin % too high?
Harbin Pharmaceutical Group Co's current EBITDA Margin % of 5.14% is 35% below median its 10-year median of 7.96. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Harbin Pharmaceutical Group Co's value of 5.14% is 58.9% below this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #673 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #673 out of 954 companies for EBITDA Margin %. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Harbin Pharmaceutical Group Co's value of 5.14% is 58.9% below this benchmark. While the company's 10-year median is 7.96 vs. the industry median of 12.52, Harbin Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current EBITDA Margin % of 5.14% is 58.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current EBITDA Margin % is 5.14%, which is 35% below median its own 10-year median of 7.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥3.14 — trading 10.5% below its estimated fair value. The current EBITDA Margin % is 5.14%, which is 35% below median its 10-year median of 7.96 and 58.9% below the Drug Manufacturers industry median of 12.52. Harbin Pharmaceutical Group Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current EBITDA Margin % is 5.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥3.14 is trading 10.5% below its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600664:
EBITDA Margin %: 5.14% (35% below median its 10-year median of 7.96)
GF Value™: ¥3.51 vs. price of ¥3.14 (10.5% below fair value)
Industry Position: 58.9% below the Drug Manufacturers median (#673 of 954)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Business Description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
78GF Score
Get the complete analysis for SHSE:600664
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
